

In the Claims:

Amend the claims as follows:

1. (Original) A peptide less than 19 amino acids in length, wherein the peptide comprises the amino sequence Leu Met Gly Thr Leu Gly Ile Val Cys Pro Ile Cys (SEQ ID NO:16).
2. (Original) The peptide of claim 1, wherein the peptide's amino acid sequence comprises Leu Leu Met Gly Thr Leu Gly Ile Val Cys Pro Ile Cys (SEQ ID NO:3).
3. (Original) The peptide of claim 1, wherein the peptide's sequence comprises Xaa Leu Met Gly Thr Leu Gly Ile Val Cys Pro Ile Cys, Xaa being Met, Ala, Ser, Arg, Lys, Gly, Gln, Asp, or Glu (SEQ ID NO:19).
4. (Original) The peptide of claim 3, wherein Xaa is Ala or Met.
5. (Original) The peptide of claim 1, wherein the peptide's sequence comprises Leu Leu Met Gly Thr Leu Gly Ile Val Cys Pro Ile Cys Ser Gln Lys (SEQ ID NO:25).
6. (Original) A peptide less than 19 amino acids in length, wherein the peptide comprises the amino acid sequence Gly Thr Leu Gly Ile Val Cys Pro Ile (SEQ ID NO:21).
7. (Original) The peptide of claim 6, wherein the peptide's sequence comprises Xaa Gly Thr Leu Gly Ile Val Cys Pro Ile Cys, Xaa being Met, Ala, Ser, Arg, Lys, Gly, Gln, Asp, or Glu (SEQ ID NO:25).
8. (Original) The peptide of claim 6, wherein the peptide's sequence comprises Met Gly Ile Val Cys Pro Ile Cys (SEQ ID NO:26).

9. (Original) The peptide of claim 7, wherein the peptide's sequence consists of Xaa Gly Thr Leu Gly Ile Val Cys Pro Ile Cys, Xaa being Met, Ala, Ser, Arg, Lys, Gly, Gln, Asp, or Glu.

10. (Original) The peptide of claim 8, wherein the peptide's sequence consists of Met Gly Thr Leu Gly Ile Val Cys Pro Ile Cys Ser Gln Lys (SEQ ID NO: 26).

11. (Original) A peptide consisting of the amino acid sequence Thr Leu Gly Ile Val Cys Pro Ile (SEQ ID NO:20).

12. (Original) A polypeptide comprising a first peptide and a second peptide linked by a peptide bond, the first peptide being a peptide which controls intracellular trafficking of a peptide to which it is attached, and the second peptide consisting of a sequence 12-18 amino acids in length comprising the sequence Leu Met Gly Thr Leu Gly Ile Val Cys Pro Ile Cys (SEQ ID NO:16).

13. (Original) The polypeptide of claim 12, wherein the sequence of the first peptide comprises the amino acid sequence Met Ala Ile Ser Gly Val Pro Val Leu Gly Phe Phe Ile Ile Ala Val Leu Met Ser Ala Gln Glu Ser Trp Ala (SEQ ID NO:18).

14. (Original) The polypeptide of claim 12, wherein the amino acid sequence of the second peptide is Xaa Leu Met Gly Thr Leu Gly Ile Val Cys Pro Ile Cys, Xaa being Met, Leu, Ala, Ser, Arg, Lys, Gly, Gln, Asp, or Glu (SEQ ID NO:19).

15. (Original) The polypeptide of claim 12, wherein the amino acid sequence of the second polypeptide is Ala Leu Met Gly Thr Leu Gly Ile Val Cys Pro Ile Cys (SEQ ID NO:4).

16. (Original) The polypeptide of claim 13, wherein the amino acid sequence of the second peptide is Xaa Leu Met Gly Thr Leu Gly Ile Val Cys Pro Ile Cys, Xaa being Met, Leu, Ala, Ser, Arg, Lys, Gly, Gln, Asp, or Glu (SEQ ID NO:19).

17. (Original) The polypeptide of claim 13, wherein the amino acid sequence of the second peptide is Ala Leu Met Gly Thr Leu Gly Ile Val Cys Pro Ile Cys (SEQ ID NO:4).

18. (Original) A polypeptide comprising a first peptide and a second peptide linked by a peptide bond, the first peptide being a peptide which controls intracellular trafficking of a peptide to which it is attached, and the second peptide consisting of a sequence 8-18 amino acids in length comprising the sequence Thr Leu Gly Ile Val Cys Pro Ile (SEQ ID NO:20). Cys Pro Ile Cys (SEQ ID NO:4).

19. (Original) A therapeutic composition comprising:

- (a) the peptide of claim 1, and
- (b) a pharmaceutically acceptable carrier.

20. (Original) A therapeutic composition comprising:

- (a) the peptide of claim 6, and
- (b) a pharmaceutically acceptable carrier.

21-69. (Canceled)